Skip to main content

Advertisement

SpringerLink
Log in

Clinical and pathologic characteristics of breast cancer patients carrying the c.3481_3491del11 mutation

  • Original Article
  • Published:
Familial Cancer Aims and scope Submit manuscript

Abstract

Tumor characteristics are used today to evaluate the possibility of mutation and to target mutation screening in families with high risk of breast and/or ovarian cancer. We studied the breast tumor profile associated to the c.3481_3491del11 French founder effect mutation on the BRCA1 gene to an attempt to identify any particularity or difference when comparing it to that related to other BRCA1 mutations. Within the population who were referred to our oncogenetic clinic at the Lorraine Oncology Institute in France and who underwent genetic testing between 1994 and 2012, we identified 404 women carrying a BRCA1 mutation. Interestingly, 45% (180/404) women had the germline c.3481_3491del11 mutation. These included 91 patients affected by first breast cancer. Clinical and pathologic data were retrieved from medical files. Descriptive statistics were conducted using the SPSS software (version 20.0). For the entire cohort of 91 women, the mean age was 43.64 years (SD 10.04). Tumors were identified in 37.4% of cases aged < 40 years. Estrogen receptor status and progesterone receptor status were reported to 67 patients. Seventy-four percent were ER negative. Hormonal receptors status was negative in 68.6% of tumors. HER2 status was available for 32 tumors. The triple-negative subtype was found in 21 cases, which accounts for 65.6% of the patients. High tumor grade was found in 81% of triple negative breast cancer patients. Based on our results compared to those of previous international studies, we concluded that the breast cancer associated to the c.3481_3491del11 is not different from that associated to other BRCA1 mutations. A larger cohort with complete information on the breast cancer pathologic characteristics and including other BRCA1 mutations would allow us to statistically compare the breast tumor profile associated to the c.3481_3491del11 to that related to other BRCA1 mutations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fricker JP, Muller D, Cutuli B, Rodier JF, Janser JC, Jung GM, Mors R, Petit T, Haegele P, Abecassis J (2000) Germ-line mutations at BRCA1 in northeastern France. Bull Cancer 87(10):739–744

    CAS  PubMed  Google Scholar 

  2. Muller D, Bonaiti-Pellié C, Abecassis J, Stoppa-Lyonnet D, Fricker JP (2004) BRCA1 testing in breast and/ or ovarian cancer families from northeastern France identifies two common mutations with a founder effect. Fam Cancer 3:15–20

    Article  CAS  Google Scholar 

  3. Janezic S, Ziogas A, Krumroy L, Krasner M, Plummer S, Cohen P (1999) Germline BRCA1 alterations in a population-based series of ovarian cancer cases. Hum Mol Genet 8(5):889–897

    Article  CAS  Google Scholar 

  4. Dong J, Chang-Claude J, Wu Y et al (1998) A high proportion of mutations in the BRCA1 gene in German breast/ovarian cancer families with clustering of mutations in the 3′ third of the gene. Hum Genet 103:154–161

    Article  CAS  Google Scholar 

  5. Atchley DP, Albarracin CT, Lopez A et al (2008) Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 26(26):4282–4288

    Article  Google Scholar 

  6. Lahkani SR, van de Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L et al (2002) The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20:2310–2318

    Article  Google Scholar 

  7. Foulkes WD, Metcalfe K, Sun P, Hanna WM et al (2004) Estrogen receptor status in BRCA1 and BRCA2 related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 10:2029–2034

    Article  CAS  Google Scholar 

  8. Veronesi A, de Giacomi C, Magri MD et al (2005) Familial breast cancer: characteristics and outcome of BRCA 1–2 positive and negative cases. BMC Cancer 5:70

    Article  Google Scholar 

  9. Brose M, Rebbeck T, Calzone Kathleen et al (2002) Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94(18):1365–1372

    Article  CAS  Google Scholar 

  10. Tung N, Wang Y, Collins L, Kaplan J, Hailun L et al (2010) Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features. Breast Cancer Res 12:R12

    Article  Google Scholar 

  11. Litwiniuk MM, Roznowski K, Filas V, Godlewski DD, Stawicka M, Kaleta R et al (2008) Expression of estrogen receptor beta in breast carcinoma of BRCA1 mutation carriers. BMC Cancer 8:100

    Article  Google Scholar 

  12. Loman N, Johannsson O, Bendahl PO, Borg A, FernÓ§ M, Olsson H (1998) Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer 83(2):310–319

    Article  CAS  Google Scholar 

  13. Johannsson OT, Idvall I, Anderson C et al (1997) Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer A 33(3):362–371

    Article  CAS  Google Scholar 

  14. Peyrat JP, Vennin P, Hornez L, Bonneterre J (1997) Mutations germinales de BRCA1 chez 36 patientes atteintes de cancer du sein et/ou de l’ovaire et appartenant à des familles à risque du Nord de la France. Bull Cancer 84(1):41–46

    CAS  PubMed  Google Scholar 

  15. Eisinger F, Bressac B, Castaigne D, Cottu PH, Lansac J, Lefranc JP et al (2004) Identification et prise en charge des prédispositions héréditaires aux cancers du sein et de l’ovaire. Bull Cancer 91:219–237

    PubMed  Google Scholar 

  16. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M et al (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24:2206–2223

    Article  CAS  Google Scholar 

  17. Musolino A, Michiara M, Bella M, Naldi N, Zanelli P et al (2005) Molecular profile and clinical variables in BRCA1-positive breast cancers: a population-based study. Tumori 91:505–512

    Article  CAS  Google Scholar 

  18. Eerola H, Heikkila P, Tamminen A et al (2005) Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 7:R93–R100

    Article  Google Scholar 

  19. Mavaddat N, Barrowdale D, Andrulis I et al (2012) Pathology of Breast and Ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the consortium of investigators of modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomark Prev 21:134–147

    Article  CAS  Google Scholar 

  20. Vaziri S, Krumrey L, Elson P et al (2001) Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis. Clin Cancer Res 7:1937–1945

    CAS  PubMed  Google Scholar 

  21. Eisinger F, Nogues C, Birnbaum D, Jacquemier J, Sobol H (1998) BRCA1 and medullary breast cancer. JAMA 280:1227–1228

    Article  CAS  Google Scholar 

  22. Claus EB, Petruzella S, Matloff E, Carter D (2005) Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. JAMA 293:964–969

    Article  CAS  Google Scholar 

  23. Hwang ES, McLennan JL, Morre DH, Crawford BB, Esserman LJ, Ziegler JL (2007) Ductal carcinoma in situ in BRCA mutation carriers. J Clin Oncol 25:642–647

    Article  Google Scholar 

  24. Smith KL, Adank M, Kauff N et al (2007) BRCA mutations in women with ductal carcinoma in situ. Clin Cancer Res 13:4306–4310

    Article  CAS  Google Scholar 

  25. Tommasi S, Crapolicchio A, Lacalamita R et al (2005) BRCA1 mutations and polymorphisms in a hospital-based consecutive series of breast cancer patients from Apulia, Italy. Mutat Res 578:395–405

    Article  CAS  Google Scholar 

  26. Comen E, Davids M, Kirchhoff T, Hudis C, Offit K, Robson M (2011) Relative contributions of BRCA1 and BRCA2 mutations to “triple-negative” breast cancer in Ashkenazi women. Breast Cancer Res Treat 129(1):185–190

    Article  CAS  Google Scholar 

  27. Noguchi S, Kasugai T, Miki Y et al (1999) Clinicopathologic analysis of BRCA1- or BRCA2-associated hereditary breast carcinoma in Japanese women. Cancer 85:2200–2205

    Article  CAS  Google Scholar 

  28. Jo´hannsson OT, Idvall I, Anderson C et al (1997) Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 33:362–371

    Article  Google Scholar 

  29. Thompson D, Easton D (2001) Breast Cancer Linkage Consortium: variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 68(2):410–419

    Article  CAS  Google Scholar 

  30. Thompson D, Easton D (2002) Breast Cancer Linkage Consortium. Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomark Prev 11(4):329–336

    CAS  Google Scholar 

  31. Lecarpentier J, Noguès C, Mouret-Fourme E, Stoppa-lyonnet D, Lasset C et al (2012) Variation in breast cancer risk with mutation position, smoking, alcohol, and chest X-ray history, in the French National BRCA1/2 carrier cohort (GENEPSO). Breast Cancer Res Treat 14:1–13

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. INSERM U954, University of Lorraine, Vandœuvre-lès-Nancy, France

    R. El Tannouri

  2. IECL CNRS, UMR 7502, BIOBASE, Pôle S2R, CHRU Nancy, InSciDens, Vandœuvre-lès-Nancy, France

    E. Albuisson

  3. Human Genetics Laboratory, CHU Brabois, INSERM U954, University of Lorraine, Vandœuvre-lès-Nancy, France

    P. Jonveaux

  4. Regional Hospital Center of Metz-Thionville UF4128, Metz, France

    E. Luporsi

Authors
  1. R. El Tannouri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Albuisson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Jonveaux
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. Luporsi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. El Tannouri.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This project was performed in compliance with the relevant ethical standards in France.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

El Tannouri, R., Albuisson, E., Jonveaux, P. et al. Clinical and pathologic characteristics of breast cancer patients carrying the c.3481_3491del11 mutation. Familial Cancer 18, 1–8 (2019). https://doi.org/10.1007/s10689-018-0079-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10689-018-0079-1

Keywords

Search

Navigation